Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05256108 · ClinicalTrials.gov registry record · Phase 1
Assessment of Abuse Potential of Cebranopadol in Humans
A Phase 1 study, sponsored by Tris Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT05256108 is a Phase 1 study that has completed, run by Tris Pharma. The registered enrollment target is 38 participants.
The verdict
NCT05256108, a Phase 1 study, has completed, sponsored by Tris Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study will be conducted to evaluate the abuse potential of single doses of cebranopadol as compared with oxycodone, tramadol and matching placebo in recreational drug users.
Interventions
- DRUG Placebo
- DRUG Cebranopadol 600 µg
- DRUG Oxycodone 40 mg
- DRUG Tramadol 600 mg
- DRUG Cebranopadol 1000 µg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2022-07-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05256108
The ClinicalTrials.gov registry entry for NCT05256108 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tris Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05256108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05256108 about?
NCT05256108 is a clinical study titled "Assessment of Abuse Potential of Cebranopadol in Humans". This study will be conducted to evaluate the abuse potential of single doses of cebranopadol as compared with oxycodone, tramadol and matching placebo in recreational drug users.
What is the current status of trial NCT05256108?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2022-03-28. Estimated completion is 2022-07-12.
What interventions are being tested in trial NCT05256108?
The interventions under investigation include: Placebo (DRUG), Cebranopadol 600 µg (DRUG), Oxycodone 40 mg (DRUG), Tramadol 600 mg (DRUG), Cebranopadol 1000 µg (DRUG).
Who is sponsoring clinical trial NCT05256108?
This trial is sponsored by Tris Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.